Pfizer (PFE)

Pfizer’s product base includes vaccines, internal medicine treatments, oncology drugs, hospital products, immunology therapies, and treatments for rare diseases. Key products include Prevnar 13, a pneumococcal vaccine, Vyndaqel for transthyretin amyloid cardiomyopathy, and Eliquis, an anticoagulant that is marketed in partnership with Bristol Myers Squibb. The company is also widely recognized for its role in vaccine development and large-scale pharmaceutical manufacturing, supported by a global commercial and supply chain network.

The business is international in scope. Pfizer sells medicines in developed markets and emerging economies, with international revenue representing a substantial share of total sales. Emerging markets are especially important because rising healthcare access, expanding insurance coverage, and growing demand for branded medicines can support long-term volume growth, although pricing and regulatory conditions vary widely by country.

Pfizer’s scale gives it advantages in research investment, clinical development, regulatory expertise, and global distribution. At the same time, the company faces typical pharmaceutical industry challenges, including patent expirations, competition from generics and biosimilars, pricing pressure, and the need to replenish its pipeline through internal research, partnerships, and acquisitions. Its investment case is closely tied to the durability of its existing drug portfolio and the success of new therapies reaching the market.